Ann: Webinar CHM Transforms Portfolio, page-28

Good to know and agree 6 months out at least for a CR. Especially the way the market is on raises ATM they wouldn’t want to do one earlier. Although PH never had any trouble rangling interest from investment in his companies. With the pipeline and management he has around CHM it would surprise me if there wasn’t a solid cornerstone or some sort of strategic investor. Correct, the timing for a raise after ASCO in June (although I feel we could get updates sooner) for Phase 1 cohort 2 read out with double the dose and dual administration would be ideal. Then SNO for cohort 3 and it’s an exciting year. Then plenty of news-flow and updates on patents, IND’s etc in the emantime.

Being under 30c is a gift and due mainly to the market and time of year IMO. Certainly generating a lot of new interest and good to see new posters coming in. Patience will be rewarded. There is some genuine interest and a real buzz around the new NK cell platform and cheers for picking it apart in your post in the separate CORE NK Platform thread. Solid write up Mate. Great way for new investors to understand what NK cells are all about and how core NK is different, super excited to see the other assets incorporated in the Car NK domain. Here is a snapshot summary excerpt from the diamond research report which valued CHM at $1.19.

The core NK platform uses membrane-bound IL-21 based NK cell feeder cells lines to activate and expand the healthy donor naked natural killer cells to make them more active and robust to combat cancer as it grows. Interleukins (IL) are a type of cytokine which helps to modulate growth, differentiation, and activation during inflammatory and immune responses. IL-21 is one of the several interleukins, which acts on various immune cells of the innate and the adaptive immune system that helps in enhancing NK cell activity. Using membrane-bound IL-21 ensures robust and sustained proliferation of highly cytotoxic NK cells. The expanded NK cells exhibit increased cytotoxic function against a panel of blood cancer and solid tumor cells compared to IL-2-activated non-expanded NK cells1. Recent clinical trials suggest that high dosages of NK cells (>109/kg) are safe and efficient. Unlike T-cells, another major potential advantage of NK cell-based therapy is that it can be carried out as off-the-shelf therapy and supports single donor expansion to treat multiple patients.

CHM doing all the right things, at the right time, very strategically!